- Hepatic Arterial Infusion Chemotherapy with Oxaliplatin Plus Raltitrexed as an Alternative Option in Advanced Hepatocellular Carcinoma Patients with Failure of, or Unsuitability for, Transarterial Chemoembolization
Yanfang Wu et al, 2022, Medicina CrossRef - Adverse events as potential predictive factors of activity in patients with advanced hepatocellular carcinoma treated with lenvatinib
Ilario Giovanni Rapposelli et al, 2021, Liver International CrossRef - A Prospective, Single-Arm, Phase 2 Study of Modified Transarterial Chemoembolization Using Low-Dose Chemotherapy with Blank Microspheres Plus Low-Dose Lenvatinib and Microwave Ablation in Patients with Large (≥7 cm) Unresectable Hepatocellular Carcinoma: The TALEM Trial
Zhi-Mei Huang et al, 2024, Liver Cancer CrossRef - Lenvatinib for Hepatocellular Carcinoma: A Literature Review
Takeshi Hatanaka et al, 2021, Pharmaceuticals CrossRef - Transarterial chemoembolization combined with lenvatinib versus transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: A systematic review and meta-analysis
Jun-Ning Liu et al, 2023, Frontiers in Oncology CrossRef - TACE Combined with Lenvatinib and Camrelizumab for Unresectable Multiple Nodular and Large Hepatocellular Carcinoma (>5 cm)
Zhanwang Xiang et al, 2023, Technology in Cancer Research & Treatment CrossRef - Optimizing the management of intermediate-stage hepatocellular carcinoma: Current trends and prospects
Takuji Torimura et al, 2021, Clinical and Molecular Hepatology CrossRef - Clinical outcomes with atezolizumab plus bevacizumab or lenvatinib in patients with hepatocellular carcinoma: a multicenter real-world study
Mara Persano et al, 2023, Journal of Cancer Research and Clinical Oncology CrossRef - Development of a Multivariate Prognostic Model for Lenvatinib Treatment in Hepatocellular Carcinoma
Xiaomi Li et al, 2023, The Oncologist CrossRef - Hepatic arterial infusion chemotherapy combined with sorafenib versus sorafenib alone for advanced hepatocellular carcinoma: a systematic review and meta-analysis
Shunyu Kong et al, 2023, Clinical Journal of Gastroenterology CrossRef - Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for patients with unresectable hepatocellular carcinoma: a systematic review and meta-analysis
Shun-Yu Kong et al, 2023, Acta Clinica Belgica CrossRef - Five years of lenvatinib in hepatocellular carcinoma: are there any predictive and/or prognostic factors?
Mara Persano et al, 2023, Expert Review of Anticancer Therapy CrossRef - Hepatic arterial infusion chemotherapy combined with lenvatinib and PD‐1 inhibitors versus lenvatinib and PD‐1 inhibitors for HCC refractory to TACE
Lingfeng Diao et al, 2024, Journal of Gastroenterology and Hepatology CrossRef - A Real-World Comparative Analysis of Lenvatinib and Sorafenib as a Salvage Therapy for Transarterial Treatments in Unresectable HCC
Jaejun Lee et al, 2020, Journal of Clinical Medicine CrossRef - Long-term complete response to lenvatinib in a patient with unresectable hepatocellular carcinoma
Morihiko Ishizaki et al, 2021, Clinical Journal of Gastroenterology CrossRef - A Retrospective Study on Therapeutic Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors Plus Lenvatinib in Patients With Unresectable Hepatocellular Carcinoma
Ying Teng et al, 2022, Technology in Cancer Research & Treatment CrossRef - Transarterial Chemoembolization Combined With PD-1 Inhibitors Plus Lenvatinib Showed Improved Efficacy for Treatment of Unresectable Hepatocellular Carcinoma Compared With PD-1 Inhibitors Plus Lenvatinib
Jinfeng Wang et al, 2023, Technology in Cancer Research & Treatment CrossRef - Multimolecular-Targeted Agents for Intermediate-Stage Hepatocellular Carcinoma Influence Time to Stage Progression and Overall Survival
Shigeo Shimose et al, 2021, Oncology CrossRef - Therapeutic Potential of Clostridium novyi-NT in Cancer: Current Knowledge and Future Perspectives
Behrouz Ebadi Sharafabad et al, 2023, Current Cancer Drug Targets CrossRef - Evolution of Systemic Treatment for Hepatocellular Carcinoma: Changing Treatment Strategies and Concepts
Michihisa Moriguchi et al, 2024, Cancers CrossRef - Efficacy and safety of Lenvatinib-based combination therapies for patients with unresectable hepatocellular carcinoma: a single center retrospective study
Jian Huang et al, 2023, Frontiers in Immunology CrossRef - Lenvatinib in combination with transarterial chemoembolization vs. sorafenib in combination with transarterial chemoembolization for unresectable hepatocellular carcinoma: A network meta‑analysis
Yong Li et al, 2024, Oncology Letters CrossRef - Addition of Camrelizumab to Transarterial Chemoembolization in Hepatocellular Carcinoma With Untreatable Progression
Yanqiao Ren et al, 2022, Technology in Cancer Research & Treatment CrossRef - Comparison of the effects of lenvatinib and sorafenib on survival in patients with advanced hepatocellular carcinoma: A systematic review and meta-analysis
Lingbo Hu et al, 2023, Clinics and Research in Hepatology and Gastroenterology CrossRef - Subsequent Treatment after Transarterial Chemoembolization Failure/Refractoriness: A Review Based on Published Evidence
Shen Zhang et al, 2022, Journal of Clinical and Translational Hepatology CrossRef - Lenvatinib: established and promising drug for the treatment of advanced hepatocellular carcinoma
Martina Catalano et al, 2021, Expert Review of Clinical Pharmacology CrossRef - Validation of the easy‐to‐use lenvatinib prognostic index to predict prognosis in advanced hepatocellular carcinoma patients treated with lenvatinib
Margherita Rimini et al, 2022, Hepatology Research CrossRef - Combination Therapy With Lenvatinib and Radiofrequency Ablation for Patients With Intermediate-Stage Hepatocellular Carcinoma Beyond Up-To-Seven Criteria and Child–Pugh Class A Liver function: A Pilot Study
Feiqian Wang et al, 2022, Frontiers in Oncology CrossRef - Lenvatinib plus transarterial chemoembolization with or without immune checkpoint inhibitors for unresectable hepatocellular carcinoma: A review
Liwei Sun et al, 2022, Frontiers in Oncology CrossRef - Efficacy and safety of hepatic artery infusion chemotherapy combined with tyrosine kinase inhibitors plus programmed death-1 inhibitors for hepatocellular carcinoma refractory to transarterial chemoembolization
Long-Wang Lin et al, 2023, Frontiers in Oncology CrossRef - The Efficacy of TACE Combined With Lenvatinib Plus Sintilimab in Unresectable Hepatocellular Carcinoma: A Multicenter Retrospective Study
Fei Cao et al, 2021, Frontiers in Oncology CrossRef - A Phase 2, Prospective, Multicenter, Single-Arm Trial of Transarterial Chemoembolization Therapy in Combination Strategy with Lenvatinib in Patients with Unresectable Intermediate-Stage Hepatocellular Carcinoma: TACTICS-L Trial
Masatoshi Kudo et al, 2024, Liver Cancer CrossRef - Real-Life Clinical Data of Lenvatinib versus Sorafenib for Unresectable Hepatocellular Carcinoma in Italy
Valentina Burgio et al, 2021, Cancer Management and Research CrossRef - Identification of lenvatinib prognostic index via recursive partitioning analysis in advanced hepatocellular carcinoma
I.G. Rapposelli et al, 2021, ESMO Open CrossRef - Thyroid Dysfunction from Treatments for Solid Organ Cancers
Anupam Kotwal et al, 2022, Endocrinology and Metabolism Clinics of North America CrossRef - Prospect of lenvatinib for unresectable hepatocellular carcinoma in the new era of systemic chemotherapy
Takuya Sho et al, 2021, World Journal of Gastrointestinal Oncology CrossRef - Tumor‐derived insulin‐like growth factor‐binding protein‐1 contributes to resistance of hepatocellular carcinoma to tyrosine kinase inhibitors
Hiroyuki Suzuki et al, 2023, Cancer Communications CrossRef - Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study
Song Chen et al, 2022, Journal of Cancer Research and Clinical Oncology CrossRef - Transcatheter arterial chemoembolization plus Sorafenib versus transcatheter arterial chemoembolization plus Lenvatinib for intermediate hepatocellular carcinoma
Moxuan Wang et al, 2024, Scientific Reports CrossRef - Efficacy Investigation of TACE Combined with Lenvatinib and Sintilimab in Intermediate-Stage Hepatocellular Carcinoma
Menglong Zhang et al, 2022, Disease Markers CrossRef - Traditional versus Microsphere Embolization for Hepatocellular Carcinoma: An Effectiveness Evaluation Using Data Mining
Pi-Yi Chang et al, 2021, Healthcare CrossRef - Transcatheter Arterial Chemoembolization for Treatment-Naive Hepatocellular Carcinoma Has Different Treatment Effects Depending on Central or Peripheral Tumor Location
Kazuo Asano et al, 2023, Liver Cancer CrossRef - Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison
Andrea Casadei-Gardini et al, 2021, Targeted Oncology CrossRef - Intermediate hepatocellular carcinoma: new horizons and prospects for our patients
Federica Lo Prinzi et al, 2024, Expert Review of Gastroenterology & Hepatology CrossRef - Recent Progress in Systemic Therapy for Hepatocellular Cancer (HCC)
T. Tara Ghaziani et al, 2021, Current Treatment Options in Gastroenterology CrossRef - Deterioration of liver function and aging disturb sequential systemic therapy for unresectable hepatocellular carcinoma
Shigeo Shimose et al, 2022, Scientific Reports CrossRef